Have SGLT-2 inhibitors DELIVERed an EMPhatic win in heart failure and chronic kidney disease?

Area of Science:

• Cardiology
• Nephrology
• Endocrinology
• Pharmacology

Background:

• Current global guidelines recommend SGLT-2 inhibitors as first-line therapy for type 2 diabetes (T2D) patients with established cardiovascular disease (eCVD), heart failure (HF), or chronic kidney disease (CKD).
• SGLT-2 inhibitors are integral to guideline-directed medical therapy for HF and CKD, irrespective of T2D status.
• These recommendations stem from robust evidence of positive cardio-renal outcomes observed in numerous randomized controlled trials (RCTs).

Purpose of the Study:

• To critically analyze RCTs evaluating the cardio-renal outcomes of SGLT-2 inhibitors.
• To provide a perspective on the efficacy of SGLT-2 inhibitors in patients with HF and CKD, with or without T2D.
• To consolidate evidence supporting the use of SGLT-2 inhibitors in cardio-renal protection.

Main Methods:

• Conducted an extensive literature search across PubMed, Google Scholar, and clinicaltrials.gov.
• Critically analyzed thirteen high-quality randomized controlled trials (RCTs).
• Included trials focused on cardiovascular outcomes (5), HF outcomes (5), renal outcomes (3), and a pooled meta-analysis.

Main Results:

• SGLT-2 inhibitors have demonstrated significant benefits in patients with HF and CKD, regardless of T2D status.
• The safety profile of SGLT-2 inhibitors in these patient populations is acceptable.
• Evidence from multiple high-quality RCTs supports the emphatic cardio-renal win for SGLT-2 inhibitors.

Conclusions:

• SGLT-2 inhibitors represent a major advancement in managing HF and CKD, offering substantial cardio-renal protection.
• The established benefits extend to patients with or without type 2 diabetes.
• Further research through ongoing RCTs will explore SGLT-2 inhibitor efficacy in other kidney diseases and conditions.